Vaccine News and Research

Latest Vaccine News and Research

Modern techniques can reduce current shortage of H1N1 vaccine in the U.S.

President Barack Obama declared H1N1 a national emergency this weekend, a status that will give the federal government greater flexibility and authority to contain the pandemic. But the current shortage of H1N1 vaccine underscores the severe lack of U.S. preparedness in responding to pandemics, whether through natural disease transmission or manmade bioterrorist attacks, according to a new video from the Commission on the Prevention of Weapons of Mass Destruction Proliferation and Terrorism.

29 Oct 2009

Poison control centers to take calls for H1N1

The same reassuring voice on the telephone line when you fear you've had a poison emergency may be the same person answering your questions about the H1N1 flu pandemic.

29 Oct 2009

Comprehensive H1N1 influenza health information centre launched in Canada

Canadians are seeking credible information concerning the H1N1 (human swine flu) virus. As a leading Canadian source of ealth information, www.medbroadcast.com has launched a one-stop comprehensive national H1N1 (human swine flu) Influenza Health information centre (www.medbroadcast.com/H1N1). This information centre will help meet the needs of Canadians in search of useful, credible, and accurate H1N1 information.

29 Oct 2009

Impact of wellness programs on pharmaceutical, diagnostic and device markets

MarketResearch.com has announced the addition of Kalorama Information's new report, "The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets," to their collection of Healthcare market reports.

29 Oct 2009

NIH awards contract to LRRI for anthrax research

Lovelace Respiratory Research Institute (LRRI) was recently awarded a contract to continue research due to the potential for bioterrorist attacks involving Bacillus anthracis, the causative agent of anthrax, by the National Institutes of Allergy and Infectious Disease (NIAID), a division of the National Institutes of Health (NIH).

29 Oct 2009

Pregnant women with symptoms of depression have a stronger biological reaction to the seasonal flu vaccine

Pregnant women with significant symptoms of depression tend to have a stronger biological reaction to the seasonal flu vaccine than do women with lower depression levels, according to a new study.

29 Oct 2009

$12.2 million grant from NIH for research on the sexually transmitted bacteria chlamydia

Perhaps the most comprehensive, multi-institutional study yet of the sexually transmitted bacteria chlamydia is under way at the University of Maryland, Baltimore (UMB).

29 Oct 2009

Gates Foundation praises U.S. global health investments, calls for 15-year goal of cutting child deaths worldwide by nearly half

As part of a "major push to convince the United States to maintain government spending on worldwide health initiatives, despite the financial crisis and a soaring U.S. budget deficit," the Bill & Melinda Gates Foundation is urging U.S. policymakers to commit to cutting "the number of child deaths each year, from 9 million to 5 million" by 2025, CNN reports (Evans, 10/28).

28 Oct 2009

CDC says U.S. H1N1 vaccine supplies on the rise; Senators question government's handling of H1N1 vaccination program

Supplies of the H1N1 (swine flu) vaccine are steadily increasing in the U.S. and should soon be more widely accessible in the next two weeks, the CDC said on Tuesday, CQ HealthBeat reports. During a press briefing, CDC Director Thomas Frieden said that 22.4 million vaccine doses are now available for states to order (Norman, 10/27). "We're beginning to get to significant increases in the availability," Frieden said.

28 Oct 2009

CDC: H1N1 vaccine supplies on the rise

"More than 22 million doses of swine flu vaccine are available now, and most Americans should soon find it easier to get their dose, U.S. health officials said Tuesday, " according to The Associated Press/The Washington Post.

28 Oct 2009

Pure Protein develops soluble Class II human leukocyte antigens

Pure Protein, L.L.C., a biopharmaceutical company specializing in diagnostic and therapeutic reagents for use in immunology research and development, has announced that Chief Scientist William Hildebrand, Ph.D., and his team, have developed soluble Class II human leukocyte antigens (HLA). This represents a significant technology breakthrough that can dramatically impact multiple pharmaceutical and medical sectors and has enormous market potential. Autoimmune disease is a key area of interest for HLA research and product development.

28 Oct 2009

SciClone Pharmaceuticals reduces its U.S.-based workforce by 17% in research and development

SciClone Pharmaceuticals, Inc. today announced a corporate restructuring that will reduce its U.S.-based workforce by approximately 17%, primarily in research and development. This restructuring follows the discontinuation of SciClone's RP101 phase 2 clinical trial announced on October 2, 2009.

28 Oct 2009

Fastest supercomputer used to create an evolutionary genetic HIV family tree

Supporting Los Alamos National Laboratory's role in the international Center for HIV/AIDS Vaccine Immunology (CHAVI) consortium, researchers are using the Roadrunner supercomputer to analyze vast quantities of genetic sequences from HIV infected people in the hope of zeroing in on possible vaccine target areas.

28 Oct 2009

NCKU transfers microalgal docosahexaenoic acid production technology to Vedan Biotechnology

NCKU President, Academician Michael Ming-Chiao Lai, signed Technology Transfer Agreement in this morning with Mr. Tou-Hsiung Yang, Chairman of Vedan International (Holding) Ltd, witnessed by Vedan Biotechnology President Shih-An (Raymond) Yang and the inventor, Prof. Huey-Lang Yang of the NCKU Institute of Biotechnology.

28 Oct 2009

Microbix and Hunan Biopharmaceutical to build $200-million influenza vaccine facility

Microbix, a developer of a patented technology that doubles the output of influenza vaccine production, announced today it has signed a joint venture agreement with the Hunan Biopharmaceutical Co. Ltd. (a Hunan Province state-owned enterprise) for initial financing to construct Asia's largest influenza vaccine production facility and the third largest vaccine plant in the world.

28 Oct 2009

PPD enters into an agreement to acquire Excel PharmaStudies

PPD, Inc. today announced it has entered into an agreement to acquire Excel PharmaStudies, Inc., the market leader and one of the largest contract research organizations in China, providing PPD additional capacity and expertise in this rapidly growing market.

28 Oct 2009

Global health promotion conference begins in Kenya, maternal mortality addressed

At the 7th Global Conference on Health Promotion, which kicked off in Kenya on Monday, participants discussed reducing maternal mortality and the related Millennium Development Goals (MDG), the Daily Nation reports. According to the newspaper, Kenyan President Mwai Kibaki "said that globally, the number of maternal deaths had … risen to 536,000 per year, translating to one death per minute."

27 Oct 2009

H1N1 overwhelms hospitals; Sebelius addresses flu vaccine shortage

Hospitals across the country are overwhelmed "as waves of flu patients arrive at their doors, doubling their emergency room volume," USA Today reports. "Just as significant is the effect on intensive care units: A relatively small number of flu patients are requiring intensive care, but some are so ill they will need round-the-clock care for weeks.

27 Oct 2009

More people rely on alternative medicine

As consumers look to save money in a tough economy, many turn to alternative health care options. CBS 4 reports: "Health care costs are soaring. Thousands of people are without jobs and without the benefits afforded them. Now, those people are turning to preventative or alternative measures. ... The National Center for Complimentary and Alternative Medicine (NCCAM) shows 38 percent of adults and 12 percent of kids are now using alternative therapies to treat pain. In fact, Americans are now reportedly spending $34 billion a year on alternative therapies" (Demos, 10/26).

27 Oct 2009

ImmunoCellular Therapeutics presents additional data from its ICT-107 Phase I clinical trial

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is focused on the development of novel immune-based cancer therapies, today announced additional data from its Phase I clinical trial evaluating ICT-107, the Company’s dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme (GBM).

27 Oct 2009

Vaccine News and Research

Latest Vaccine News and Research

Modern techniques can reduce current shortage of H1N1 vaccine in the U.S.

Poison control centers to take calls for H1N1

Comprehensive H1N1 influenza health information centre launched in Canada

Impact of wellness programs on pharmaceutical, diagnostic and device markets

NIH awards contract to LRRI for anthrax research

Pregnant women with symptoms of depression have a stronger biological reaction to the seasonal flu vaccine

$12.2 million grant from NIH for research on the sexually transmitted bacteria chlamydia

Gates Foundation praises U.S. global health investments, calls for 15-year goal of cutting child deaths worldwide by nearly half

CDC says U.S. H1N1 vaccine supplies on the rise; Senators question government's handling of H1N1 vaccination program

CDC: H1N1 vaccine supplies on the rise

Pure Protein develops soluble Class II human leukocyte antigens

SciClone Pharmaceuticals reduces its U.S.-based workforce by 17% in research and development

Fastest supercomputer used to create an evolutionary genetic HIV family tree

NCKU transfers microalgal docosahexaenoic acid production technology to Vedan Biotechnology

Microbix and Hunan Biopharmaceutical to build $200-million influenza vaccine facility

PPD enters into an agreement to acquire Excel PharmaStudies

Global health promotion conference begins in Kenya, maternal mortality addressed

H1N1 overwhelms hospitals; Sebelius addresses flu vaccine shortage

More people rely on alternative medicine

ImmunoCellular Therapeutics presents additional data from its ICT-107 Phase I clinical trial

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Vaccine News and Research

Latest Vaccine News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in